

NETSTAP e.V.



Netzwerk Kinder- und Jugendärzte für klinische Studien in der Ambulanten Pädiatrie

(network of pediatricians for clinical
studies in ambulant treatment)

www.netstap.de

board and office



Board:

- Prof. Dr. A. Bufe, Bochum
- Dr. R. Ebert, Tauberbischofsheim
- Dr. F. Kaiser, Hamburg
- Dr. R. Knecht, Bretten
- Dr. B. Sandner, Aschaffenburg
- R. Köllges, Mönchengladbach
- Dr. C. Gronke, Ludwigsfelde

Office:

NETSTAP e.V.

Frau Eike Stöckmann

Forschungszentrum Borstel

Parkallee 35

23845 Borstel

Tel: 04537-188 7110

FAX: 04537-188 7470

Email:

estoeckmann@fz-borstel.de

Vorstand und Geschäftsstelle

NETSTAP
NETZIV



members

- about 100 pediatricians in surgeries or clinical ambulances in Germany.
- confidentiality agreement members → NETSTAP




member profile

- GCP-ICH certified, study experience
- Specialists (>95% pediatricians)
- Specific features: allergological and pneumological diseases, vaccinations
- Trained personnel
- Constant quality management

development of members 2002-2017

Number of members



aims and implementation


- Regular support of training for investigators and studynurses according to „Good Clinical Practice“ (GCP-ICH)
- since 2002 regular offer of certified GCP-ICH basic, progressive and refresher courses.



aims and implementation



- Networking of members
 - protected intranet specially provided for NETSTAP members
 - special folder for each study (quality management)



aims and implementation

- improving environment for clinical studies in child and adolescence population (evidence based medicine)
- promoting studies and study designs suitable for children



Support and consulting of Sponsor

current studies

- Study for sublingual immunotherapy 2018-2021
- Individual attendance on several trials
(single NETSTAP-members) 2016-2019

publication (completed studies)

- Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms ***Allergy (2004); 59: 498-504***
- Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children ***Pediatric Allergy and Immunology (2007); 18: 516-522***
- Safety and efficacy in children of an SQ-standardised grass allergen tablet for sublingual immunotherapy ***J Allergy Clin Immunol (2009); 123: 167-73***
- Clinical efficacy of the ALK house dust mite allergy immunotherapy tablet correlates with immunological endpoints ***Allergy 65 (Suppl. 92):174-175***
- High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe ***J Allergy Clin Immunol. 2012 Oct;130(4):886-93***
- Design and recruitment for the GAP trail, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen- induced allergic rhinoconjunctivitis ***Clin Ther. 2011 Oct;33(10):1537-46***

publication (completed studies)

- Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With and Without Routine Infant Vaccinations According to Different Immunization Schedules **JAMA 2012; 307:573-582**
- Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. **Lancet 2013; 12:61961-8.**
- Infant formula containing galacto-and fructo-oligosaccharides and Bifidobacterium breve M-16V supports adequate growth and tolerance in healthy infants in a randomised, controlled, double-blind, prospective, multicentre study **(2016) J Nutr Sci; 5, e42:1-13**
- Side effects during subcutaneous immunotherapy (SCIT) in children with allergic diseases. **(2018) Pediatr Allergy Immunol; 29:267-274**